Molecular neuropsychology: Creation of test-specific blood biomarker algorithms

Dementia and Geriatric Cognitive Disorders

Volumn 37, Issue 1-2, 2014, Pages 45-57

  O'Bryant, Sid E ^a   Xiao, Guanghua ^c   Barber, Robert ^b   Cullum, C Munro ^c,d   Weiner, Myron ^c,d   Hall, James ^a   Edwards, Melissa ^e   Grammas, Paula ^f   Wilhelmsen, Kirk ^g   Doody, Rachelle ^h   Diaz Arrastia, Ramon ⁱ  

^a Fort Worth Texas College of Osteopathic Medicine   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF NORTH TEXAS   (United States)

^f TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Algorithms; Biomarkers; Molecular markers; Neuropsychology; Psychology

Indexed keywords

BIOLOGICAL MARKER; AGOUTI RELATED PROTEIN; ALPHA 2 MACROGLOBULIN; BETA 2 MICROGLOBULIN; CREATINE KINASE MB; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; PANCREAS POLYPEPTIDE; PROTEIN S100B; STEM CELL FACTOR; THYROID PEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ALGORITHM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MOLECULAR NEUROPSYCHOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PRIORITY JOURNAL; RANDOM FOREST; AGED; ALGORITHM; AMERICAN NATIONAL ADULT READING TEST; BOSTON NAMING TEST; CLOCK DRAWING TEST; DEMOGRAPHY; DIGIT SPAN; MINI MENTAL STATE EXAMINATION; PSYCHOLOGIC TEST; RISK ASSESSMENT; SCORING SYSTEM; STORY MEMORY SCALE; UNITED STATES; WECHSLER MEMORY SCALE;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; COGNITION; COHORT STUDIES; FEMALE; HUMANS; INTELLIGENCE; LINEAR MODELS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NEUROPSYCHOLOGY;

EID: 84896735501     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000345605     Document Type: Article

References (48)

1. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, Waring S, Diaz-Arrastia R: A serum protein-based algorithm for the detection of Alzheimer disease. Arch Neurol 2010; 67: 1077-1081.
2. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
3. Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, Maetzler W: Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. Dement Geriatr Cogn Disord 2011; 31: 413-416.
4. O'Bryant SE, Hobson VL, Hall JR, Barber RC, Zhang S, Johnson L, Diaz-Arrastia R: Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement Geriatr Cogn Disord 2011; 31: 31-36.
5. Mayer AR, Mannell MV, Ling J, Gasparovic C, Yeo RA: Functional connectivity in mild traumatic brain injury. Hum Brain Mapp 2011; 32: 1825-1832.
6. Li J, Li XY, Feng DF, Pan DC: Biomarkers associated with diffuse traumatic axonal injury: exploring pathogenesis, early diagnosis, and prognosis. Trauma 2010; 69: 1610-1618.
7. Xiong P, Zeng Y, Wan J, XiaoHan DH, Tan D, Lu J, Xu F, Li Hy, Zhu Z, Ma M: The role of NGF and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res 2011; 189: 72-76.
8. Levin Y, Wang L, Schwarz E, Koethe D, Leweke FM, Bahn S: Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 2010; 15: 1088-1100.
9. Taurines R, Dudley E, Grassl J, Warnke A, Gerlach M, Coogan AN, Thome J: Review: proteomic research in psychiatry. J Psychopharmacol 2011; 25: 151-196.
10. Hall J, O'Bryant SE, Johnson LA, Barber RC: Depression and brain-derived neurotrophic factor levels in Alzheimer's disease. Neurosci Med 2011;2:43-47.
11. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Gabriela Nielsen M, Placentino A, Giovannini C, Rillosi L, Ventriglia M, Riva MA, et al: Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 2010; 11: 763-773.
12. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R, Texas Alzheimer's Research & Care Consortium, Alzheimer's Disease Neuroimaging Initiative: A bloodbased screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS ONE 2011; 6:e28092.
13. O'Bryant S, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, Doody R, Fairchild T, Adams P, Wilhelmsen K, Diaz-Arrastia R: A blood based algorithm for the detection of Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 32: 55-62.
14. Vemuri P, Gunter JL, Senjem ML, Whitwell JL, Kantarci K, Knopman DS, Boeve BF, Petersen RC, Jack CR Jr: Alzheimer's disease diagnosis in individual subjects using structural MR images: validation studies. Neuroimage 2008; 39: 1186-1197.
15. Zhang D, Wang Y, Zhou L, Yuan H, Shen D, Alzheimer's Disease Neuroimaging Initiative: Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 2011; 55: 856-867.
16. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, et al: Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 2009; 16: 351-362.
17. Benoit CE, Rowe WB, Menard C, Sarret P, Quirion R: Genomic and proteomic strategies to identify novel targets potentially involved in learning and memory. Trends Pharmacol Sci 2011; 32: 43-52.
18. Shaw LM, Korecka M, Clark CM, Lee VM, Trojanowski JQ: Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007; 6: 295-303.
19. Schneider P, Hampel H, Buerger K: Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 2009; 15: 358-374.
20. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
21. O'Bryant SE, Waring SC, Hobson V, Hall JR, Moore CB, Bottiglieri T, Massman P, Diaz-Arrastia R: Decreased C-reactive protein levels in Alzheimer disease. J Geriatr Psychiatry Neurol 2010; 23: 49-53.
22. Wilson JS, Mruthinti S, Buccafusco JJ, Schade RF, Mitchell MB, Harrell DU, Gulati NK, Miller LS: Anti-RAGE and Aβ immunoglobulin levels are related to dementia level and cognitive performance. J Geront A Biol Sci Med Sci 2009; 64: 264-271.
23. Randolph C: Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, Psychological Corporation, 1998.
24. Beers SR, Berger RP, Adelson PD: Neurocognitive outcome and serum biomarkers in inflicted versus noninflicted traumatic brain injury in young children. J Neurotrauma 2007; 24: 97-105.
25. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P: Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005; 64: 1371-1377.
26. Waring S, O'Bryant SE, Reisch JS, Diaz-Arrastia R, Knebl J, Doody R, Texas Alzheimer's Research Consortium: The Texas Alzheimer's Research Consortium longitudinal research cohort: study design and baseline characteristics. Texas Public Health J 2008; 60: 9-13.
27. McKhann D, Drockman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group. Neurology 1984; 34: 939-944.
28. Wechsler D: Wechsler Memory Scale, ed 3. San Antonio, Psychological Corporation, 1997.
29. Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment, ed 4. Oxford, Oxford University Press, 2004.
30. Strauss E, Sherman EMS, Spreen O: A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, ed 3. Oxford, Oxford University Press, 2006.
31. Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997; 1: 173-176.
32. Ivnik R, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, Kurkland LT: Mayo's Older Americans Normative Studies: WAIS-R norms for age 56 to 97. Clin Neuropsychol 1992; 6: 1-30.
33. Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC: Neuropsychological tests' norms above age 55 COWAT, BNT, MAE Token, WRAT-R Reading, AMNART, STROOP, TMT and JLO. Clin Neuropsychol 1996; 10: 262-278.
34. Psychological Corporation: WAIS-III-WMS-III Technical Manual. San Antonio, Psychological Corporation, 1997.
35. Hobson V, Hall JR, Harvey M, Cullum CM, Lacritz L, Massman PJ, Waring SC, O'Bryant SE: An examination of the Boston Naming Test: calculation of 'estimated' 60-item score from 30-and 15-item scores in a cognitively impaired population. Int J Geriatr Psychiatry 2011; 26: 351-355.
36. R: a language and environment for statistical computing. http://www.R-project.org.
37. Breiman L: Random forests. Machine Learning 2001; 45: 5-32.
38. Manual on setting up, using, and understanding random forests V3.1. http://oz.berkeley.edu/users/breiman/Using-random-forests-V3.1.pdf.
39. Wu B, Abbott T, Fishman D, McMurray W, Mor G, Stone K, Ward D, Williams K, Zhao H: Comparison of statistical methods for classification of ovarian cancer using a proteomics dataset. Bioinformatics 2003; 19: 1636-1643.
40. Díaz-Uriarte R, Alvarez de Andrés S: Gene selection and classification of microarray data using random forest. BMC Bioinformatics 2006; 7: 3.
41. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH: Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007; 61: 120-129.
42. Lehmann C, Koenig T, Jelic V, Prichep L, John RE, Wahlund LO, Dodge Y, Dierks T: Application and comparison of classification algorithms for recognition of Alzheimer's disease in electrical brain activity (EEG). J Neurosci Methods 2007; 161: 342-350.
43. Tripoliti EE, Fotiadis DI, Argyropoulou M: A supervised method to assist the diagnosis of Alzheimer's disease based on functional magnetic resonance imaging. Conf Proc IEEE Eng Med Biol Soc 2007: 3426-3429.
44. Tripoliti EE, Fotiadis DI, Argyropoulou M: An automated supervised method for the diagnosis of Alzheimer's disease based on fMRI data using weighted voting schemes. IEEE 2008; 2008: 340-345.
45. Strobl C, Boulesteix AN, Zeileis A, Hothorn T: Bias in random forest variable importance measures: illustrations, sources and a solution. BMC Bioinformatics 2007; 8: 25.
46. Musicco M, Salamone G, Caltagirone C, Cravello L, Fadda L, Lupo F, Mosti S, Perri R, Palmer K: Neuropsychological predictors of rapidly progressing patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2010; 30: 219-228.
47. Jungwirth S, Zehetmayer S, Bauer P, Weissgram S, Tragl KH, Fischer P: Prediction of Alzheimer dementia with short neuropsychological instruments. J Neural Transm 2009; 116: 1513-1521.
48. Lopez LM, Mullen W, Zürbig P, Harris SE, Gow AJ, Starr JM, Porteous DJ, Mischak H, Deary IJ: A pilot study of urinary peptides as biomarkers for intelligence in old age. Intelligence 2011; 39: 46-53.